Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

• Sponsor: GlaxoSmithKline (Industry)
• Overall Status: Terminated
• CT.gov ID: NCT01435993
• Collaborator: (none)
• Enrollment: 3
• Locations: 2
• Arms: 2
• Actual Duration (Months): 4.5
• Patients Per Site: 1.5
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

This study will investigate an experimental new drug, GSK1223249 in patients diagnosed with relapsing forms of multiple sclerosis. The study will specifically investigate safety (vital signs like heart rate, blood pressure, Magnetic Resonance Imaging (MRI), and other markers of health from blood samples), tolerability (any side effects that occur, if any), and pharmacokinetics (how the body processes the drug and how long the drug stays in the blood, and in cerebro-spinal fluid). The study will also investigate if patients' own immune system interacts with GSK1223249.

Condition or Disease	Intervention/Treatment	Phase
Multiple Sclerosis, Relapsing-Remitting	Drug: GSK1223249; Other: Saline placebo	Phase 1

Detailed Description

This study will be a randomised, placebo-controlled, single-blind (Investigator and Subject), single and repeat ascending dose protocol, in multiple sclerosis patients. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and any potential for immunogenicity of GSK1223249 (a monoclonal antibody raised against Nogo-A), given intravenously in Multiple Sclerosis patients. The study will also evaluate exploratory endpoints including para-clinical activity via magnetic resonance imaging, cerebrospinal fluid pharmacokinetics, and effect of repeat dose administration of GSK1223249 on disability. Furthermore MS symptoms, such as relapses and individual symptom severity will be closely monitored.

Study Design

• Study Type: Interventional
• Actual Enrollment: 3 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.
• Actual Study Start Date: Sep 8, 2011
• Actual Primary Completion Date: Jan 23, 2012
• Actual Study Completion Date: Jan 23, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Active GSK1223249 slow (60 minutes) intravenous infusion	Drug: GSK1223249; Intravenous infusion
Placebo Comparator: Placebo Saline slow (60 minutes) intravenous infusion	Other: Saline placebo; placebo intravenous infusion

Outcome Measures

Primary Outcome Measures

1. Safety [every 2-4 weeks over 7 months]

   • Changes in vital signs, ECG monitoring, blood chemistry, haematology, urinalysis, monitoring of AEs and MS relapses (number, incidence, severity)

Secondary Outcome Measures

1. Cmax values and AUC(0-∞) [Pre-dose; 1hr; 6hr; 12hr; 48hr; Day7; Day13; Follow-up]

   Profile of Pharamcokinetics

2. Immunogenicity of GSK1223249 in MS patients [Predose; Day 85; Day169; Day197]

   • Presence of antibodies to GSK1223249 to be assessed in serum samples using validated ECL assays.

3. Pharmacokinetics of GSK1223249 in cerebro-spinal fluid (CSF) in MS patients [Day7; or Day 29; or Day 35; or Day 85]

   Measurement of GSK1223249 in CSF

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 60 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Diagnosed with a relapsing form of MS .

• Using one of the following ongoing MS treatment strategies, defined as

1. Currently receiving Beta-interferon/Copaxone for treatment of MS and have been receiving the current course of therapy for 3 or more months prior to screening, OR

2. Not currently receiving disease modifying therapies for treatment of MS, and has not received such therapies for at least 3 months prior to screening.

• Demonstrated clinical activity in 2 years prior to screening, whilst receiving current/previous treatment regimen or prior to any treatment regimen

• Expanded Disability Status Scale (EDSS) score ≤6.0 at either the screening or baseline visit.

• Male or female between 18 and 60 years of age inclusive, at the time of signing the informed consent.

• Body weight equal to or greater than: 50 kilogrammes

Exclusion Criteria:

• Complications/History of other diseases that may impact on safety of patients enroling into the study.

• Liver function test outside normal range for patient population

• Treatment with methylprednisolone or any other systemic steroid, for a relapse or otherwise, within 30 days of screening

• Treatment in the past 6 months with any of the following agents: Fingolimod (Gilenya), methotrexate, mitoxantrone, azathioprine, or other small molecule immunosuppressants.

• History of anaphilaxis to protein based therapeutics or mono-clonal antibodies.

• Positive result for Hapatitis B, HIV, and/or drugs of abuse, or excessive alcohol consumption.

• Not able to undergo MRI scanning safely, or Gadolinium (contrast enhancing agents) during MRI.

• Other significant infections e.g. Tuberculosis.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Verona	Veneto	Italy	37134
2	GSK Investigational Site	Lørenskog		Norway	1478

Sponsors and Collaborators

• GlaxoSmithKline

Investigators

• Study Director: GSK Clinical Trials, GlaxoSmithKline

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: GlaxoSmithKline
• ClinicalTrials.gov Identifier: NCT01435993
• Other Study ID Numbers: 114840; 2010-022664-12
• First Posted: Sep 19, 2011
• Last Update Posted: Nov 24, 2020
• Last Verified: Nov 1, 2020

• Keywords provided by GlaxoSmithKline: Multiple Sclerosis, Secondary-Progressive with relapses
• Additional relevant MeSH terms: Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sclerosis

Study Results

No Results Posted as of Nov 24, 2020